Exclusive: Epstein’s tissue samples ignited furor in Harvard lab

Thirteen years later, the whereabouts of the sex offender's skin cells are a mystery. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 24, 2026 Check out STAT+

Sponsored By

Camille MacMillin/STAT; Photo: Jon Elswick/AP STAT+ | Jeffrey Epstein's tissue samples ignited a furor in the Harvard lab of George Church Researcher threatened to quit over special treatment for a 'bad person' who had steered donations to George Church's Personal Genome Project. By Megan Molteni STAT+ | Will Novo Nordisk's slashing of obesity drug prices save patients' money? It depends In the complicated world of drug pricing, cutting the list price doesn't always change net prices, the actual cost to insurers after rebates and discounts. By Elaine Chen STAT+ | Digital twins, the holy grail of preventative health, are still only a 'Frankensteinian proof of principle' In the race to build digital twins of human patients, computing costs and data gaps are high hurdles. "It's a lot more complex than people had envisioned." By Mohana Ravindranath Illustration: Camille MacMillin/STAT; Photos: Adobe STAT+ | New treatment approach could give IBD patients hope, and be a bonanza for drugmakers AbbVie, Lilly, Pfizer, Merck, and J&J bet big on new treatments for Crohn's disease and ulcerative colitis. Upcoming trial data could reshape a $20B market. By Allison DeAngelis STAT+ | In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding   Telehealth giant reports 2025 growth in revenue and subscribers, says 2026 weight loss business is "durable." By Katie Palmer STAT+ | Drugmakers lay out their legal arguments against Trump's drug pricing experiments As Medicare prepares pilot projects to tie U.S. drug prices to those paid overseas, comments filed on the proposals signal future legal challenges. By John Wilkerson Stephen Maturen/Getty Images) Opinion: It's time for a new era of advocacy for physicians Physician advocacy has long been quiet. But in this moment, doctors must speak loudly about policy. By Sarah C. Nosal STAT+ | Opinion: Optum CMO: Doctors must take responsibility for patient outcomes Our new research makes a powerful case for scaling value-based care more widely, writes Optum's chief medical officer. By Ken Cohen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser